Unfortunately, in some cases, the antitumoral inefficacy of NF-κB inactivation in thyroid cancer cells has been proven, as well as the failure of NF-κB inhibition to improve the therapeutic effects of antineoplastic drugs. The gene discussed is NFKB1; the disease is thyroid cancer.